Abstract:
The subject invention pertains to a modified MCIR peptide ligand comprising a peptide that is a melanocortin 1 receptor (MCIR) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MCIR peptide ligand can be coupled, e.g. , via a click reaction with a complementary click functionality attached, to a moiety to form an MClR-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MCIR. The subject invention also pertains to a MCIR peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MCIR or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
Abstract:
Disclosed are isolated Chlamydia trachomatis proteins, methods of fusion protein and associated antibody production, and methods of using isolated proteins and antibodies in diagnosis and detection. Also disclosed are compositions comprising isolated proteins, wherein the compositions can further comprising pharmaceutically acceptable carriers, an adjuvant and/or an immunostimulant, and methods using the pharmaceutical compositions for treating or preventing an infection by Chlamydia in a subject. The compositions may also comprise a protein or immunogenic fragment of a pathogenic organism other than Chlamydia trachomatis.
Abstract:
A method, system and computer program product for dynamically composing processor cores to form logical processors. Processor cores are composable in that the processor cores are dynamically allocated to form a logical processor to handle a change in the operating status. Once a change in the operating status is detected, a mechanism may be triggered to recompose one or more processor cores into a logical processor to handle the change in the operating status. An analysis may be performed as to how one or more processor cores should be recomposed to handle the change in the operating status. After the analysis, the one or more processor cores are recomposed into the logical processor to handle the change in the operating status. By dynamically allocating the processor cores to handle the change in the operating status, performance and power efficiency is improved.
Abstract:
A method and processor for providing full load/store queue functionality to an unordered load/store queue for a processor with out-of-order execution. Load and store instructions are inserted in a load/store queue in execution order. Each entry in the load/store queue includes an identification corresponding to a program order. Conflict detection in such an unordered load/store queue may be performed by searching a first CAM for all addresses that are the same or overlap with the address of the load or store instruction to be executed. A further search may be performed in a second CAM to identify those entries that are associated with younger or older instructions with respect to the sequence number of the load or store instruction to be executed. The output results of the Address CAM and Age CAM are logically ANDed.
Abstract:
The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.
Abstract:
Pharmaceutical compositions comprising compounds of the formula (I) where R 1 , R 2 , and R 3 are described here, have therapeutic utility in selectively inhibiting P. falciparum dihydroorotate dehydrogenase. Accordingly, such compositions have use in the treatment and prevention of malaria.
Abstract:
The invention relates to the synthesis and complete stereochemical assignments of cytotoxic compounds such as compound 28-a and its stereoisomers. The invention further provides processes for making the compounds, their synthetic intermediates, and for methods of using the compounds and their pharmaceutical compositions for the treatment of neoplastic diseases.
Abstract:
Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (C max ) of at least about 0.25 μg/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.
Abstract:
The present invention provides an isolated nucleic acid encoding a novel lactate dehydrogenase (LDH) as well as the isolated LDH polypeptide. Also provided are methods of enhancing fuel-stimulated insulin secretion, in particular, glucose-stimulated insulin secretion. Further provided are methods of screening for compounds that bind LDH, modulate LDH activity, and/or modulate fuel- or glucose-stimulated insulin secretion and the compounds identified thereby. The invention further provides a method of enhancing insulin secretion by administering a nucleic acid encoding LDH to a subject in a therapeutically effective amount.
Abstract:
The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, ABCG8. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of ABCG8.